GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Schott Pharma AG & CO KGaA (CHIX:1SXPd) » Definitions » GF Value

Schott Pharma AG KGaA (CHIX:1SXPD) GF Value : €20.24 (As of Dec. 13, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Schott Pharma AG KGaA GF Value?

As of today (2024-12-13), Schott Pharma AG KGaA's share price is €25.68. Schott Pharma AG KGaA's GF Value is €20.24. Therefore, Schott Pharma AG KGaA's Price-to-GF-Value for today is 1.27. Based on the relationship between the current stock price and the GF Value, GuruFocus believes Schott Pharma AG KGaA is Modestly Overvalued.

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

  1. Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
  2. GuruFocus adjustment factor based on the company’s past returns and growth.
  3. Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

Schott Pharma AG KGaA  (CHIX:1SXPd) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)Predictable Companies that possibly be Value Traps
Significantly OvervaluedPredictable Companies which are Significantly Overvalued
Modestly OvervaluedPredictable Companies which are Modestly Overvalued
Fairly ValuedPredictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Schott Pharma AG KGaA's Price-to-GF-Value for today is calculated as

Price-to-GF-Value=Share Price/GF Value
=25.68/20.24
=1.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Schott Pharma AG KGaA GF Value Related Terms

Thank you for viewing the detailed overview of Schott Pharma AG KGaA's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Schott Pharma AG KGaA Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Schott Pharma AG & CO KGaA (CHIX:1SXPd) » Definitions » GF Value
Comparable Companies
Traded in Other Exchanges
1SXP:Germany 1SXP:Austria
Address
Hattenbergstrasse 10, Mainz, RP, DEU, 55122
Website
https://www.schott-pharma.com
Schott Pharma AG & CO KGaA caters to the pharma, biotech and life science industry by providing containment solutions and delivery systems for injectable drugs. Its segments include; Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of the revenue is generated from Drug Containment Solutions segment which includes products like vials, cartridges and ampoules for safe drug containment. Geographically, the company generates revenue from Europe, Middle East, Africa (EMEA), Asia and South Pacific, North America and South America.

Schott Pharma AG KGaA Headlines

No Headlines